Amicus Therapeutics Inc. (FOLD)
NASDAQ: FOLD
· Real-Time Price · USD
7.24
0.12 (1.69%)
At close: Aug 15, 2025, 10:01 AM
1.69% (1D)
| Bid | 7.24 |
| Market Cap | 2.23B |
| Revenue (ttm) | 571.16M |
| Net Income (ttm) | -38.1M |
| EPS (ttm) | -0.12 |
| PE Ratio (ttm) | -60.29 |
| Forward PE | 24.14 |
| Analyst | Buy |
| Ask | 7.25 |
| Volume | 448,097 |
| Avg. Volume (20D) | 4,858,400 |
| Open | 7.20 |
| Previous Close | 7.12 |
| Day's Range | 7.17 - 7.31 |
| 52-Week Range | 5.51 - 12.65 |
| Beta | 0.53 |
About FOLD
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol FOLD
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for FOLD stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Amicus Therapeutics Inc. is scheduled to release its earnings on
Nov 5, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
4 weeks ago
+3.62%
Amicus Therapeutics shares are trading higher afte...
Unlock content with
Pro Subscription
3 months ago
-13.02%
Amicus Therapeutics shares are trading lower after the company reported mixed Q1 financial results.
1 week ago · fool.com
Amicus (FOLD) Q2 Revenue Jumps 22%Amicus (FOLD) Q2 Revenue Jumps 22%
2 months ago · seekingalpha.com
Amicus Therapeutics: Opportunity Awaits In This Beaten Down PharmaAmicus Therapeutics is a commercial-stage biotech with a focused pipeline in Fabry, Pompe, and rare kidney diseases. Galafold, its lead therapy, is the only approved oral treatment for Fabry disease a...
